238 related articles for article (PubMed ID: 30966822)
1. Sodium-glucose co-transporter 2 inhibitors for the prevention of heart failure in type 2 diabetes: A systematic review and meta-analysis.
Yamani N; Usman MS; Akhtar T; Fatima K; Asmi N; Khan MS
Eur J Prev Cardiol; 2020 Apr; 27(6):667-670. PubMed ID: 30966822
[No Abstract] [Full Text] [Related]
2. Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
Greene SJ; Butler J
Circulation; 2019 Jan; 139(2):152-154. PubMed ID: 30615507
[No Abstract] [Full Text] [Related]
3. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
Savarese G; Sattar N; Januzzi J; Verma S; Lund LH; Fitchett D; Zeller C; George JT; Brueckmann M; Ofstad AP; Inzucchi SE; Wanner C; Zinman B; Butler J
Circulation; 2019 Mar; 139(11):1458-1460. PubMed ID: 30855996
[No Abstract] [Full Text] [Related]
5. Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?
Testani JM; Inzucchi SE; Voors AA
Circulation; 2019 May; 139(21):2383-2385. PubMed ID: 31107618
[No Abstract] [Full Text] [Related]
6. Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE-TIMI 58 for the basic science community.
Kondo H; Takahashi N
Cardiovasc Res; 2019 May; 115(6):e54-e57. PubMed ID: 31077584
[No Abstract] [Full Text] [Related]
7. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
8. Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications.
Bassi N; Fonarow GC
Curr Cardiol Rep; 2018 Sep; 20(11):112. PubMed ID: 30259198
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification tools for heart failure in the diabetes clinic.
Cannistraci R; Mazzetti S; Mortara A; Perseghin G; Ciardullo S
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1070-1079. PubMed ID: 32475628
[TBL] [Abstract][Full Text] [Related]
10. Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure.
Honigberg MC; Vardeny O; Vaduganathan M
Circ Heart Fail; 2020 Feb; 13(2):e006623. PubMed ID: 32059632
[No Abstract] [Full Text] [Related]
11. Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.
Giugliano D; Longo M; Scappaticcio L; Caruso P; Esposito K
Cardiovasc Diabetol; 2021 Jan; 20(1):17. PubMed ID: 33430860
[TBL] [Abstract][Full Text] [Related]
12. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
Katsiki N; Triposkiadis F
Curr Vasc Pharmacol; 2019; 17(4):421-424. PubMed ID: 30173648
[No Abstract] [Full Text] [Related]
13. The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
Butler J; Anker SD
Circulation; 2017 Oct; 136(16):1459-1461. PubMed ID: 29038205
[No Abstract] [Full Text] [Related]
14. Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Arnott C; Li Q; Kang A; Neuen BL; Bompoint S; Lam CSP; Rodgers A; Mahaffey KW; Cannon CP; Perkovic V; Jardine MJ; Neal B
J Am Heart Assoc; 2020 Feb; 9(3):e014908. PubMed ID: 31992158
[TBL] [Abstract][Full Text] [Related]
15. Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care.
Tanaka A; Node K
Cardiovasc Diabetol; 2020 Sep; 19(1):132. PubMed ID: 32878601
[TBL] [Abstract][Full Text] [Related]
16. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
Figtree GA; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B
Circulation; 2019 May; 139(22):2591-2593. PubMed ID: 30882240
[No Abstract] [Full Text] [Related]
17. Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Qiu M; Ding LL; Zhan ZL; Zhou HR
Front Endocrinol (Lausanne); 2021; 12():664502. PubMed ID: 33841341
[No Abstract] [Full Text] [Related]
18. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
Vaduganathan M; Januzzi JL
Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
[TBL] [Abstract][Full Text] [Related]
19. Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink.
Sattar N; McGuire DK
Circulation; 2018 Jul; 138(1):7-9. PubMed ID: 29967228
[No Abstract] [Full Text] [Related]
20. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
Rådholm K; Figtree G; Perkovic V; Solomon SD; Mahaffey KW; de Zeeuw D; Fulcher G; Barrett TD; Shaw W; Desai M; Matthews DR; Neal B
Circulation; 2018 Jul; 138(5):458-468. PubMed ID: 29526832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
